Actigraph
Actigraph is recorded as a service provider in 33 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 33 trials · Latest update first
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.
Sponsor H. Lundbeck A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
AN OPEN-LABEL, EXPLORATORY STUDY OF THE SAFETY AND PRELIMINARY EFFICACY OF DANICAMTIV IN STABLE AMBULATORY PARTICIPANTS WITH PRIMARY DILATED CARDIOMYOPATHY DUE TO EITHER MYH7 OR TTN VARIANTS OR OTHER CAUSALITIES
Sponsor Myokardia Inc.
- Start (EU)
- Latest update
- Estimated end
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, multi-center, randomized, parallel-group, open-label, non-inferiority study evaluating the efficacy, safety, and tolerability of oral dolutegravir/lamivudine once-daily as a first-line regimen compared to oral bictegravir/emtricitabine/tenofovir alafenamide once daily for virologic suppression and maintenance in antiretroviral therapy naive adults living with HIV
Sponsor Viiv Healthcare UK Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with Colorectal Cancer who have Cancer Cachexia (SAPPHIRE)
Sponsor Ngm Biopharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
Sponsor Dyne Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination with Tirzepatide in Participants with Obesity or Overweight with at least One Weight-Related Comorbidity
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dosefinding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
C3651003 A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)
Sponsor Nido Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in participants with knee osteoarthritis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Actigraph?
The 2026-10-09 snapshot links Actigraph to 33 distinct CTIS trials. Recorded services include Actigraphy, Electronic data capture, Accelerometry, Actigraphy data, among 28 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Actigraph?
The most frequently recorded therapeutic areas are Neurology, Solid Tumor Oncology, Gastroenterology, Nutrition. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Actigraph conducted?
The linked trials record locations in 25 countries, including Spain, Germany, Poland, France, Italy. These are trial locations, not confirmed office locations or countries where Actigraph delivered services.
What can this page tell me about Actigraph's trial experience?
Browse 33 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Actigraph. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Actigraph LLC